Day One Biopharmaceuticals
DAWN
DAWN was delisted on the 22nd of April, 2026.
157 hedge funds and large institutions have $1.03B invested in Day One Biopharmaceuticals in 2024 Q2 according to their latest regulatory filings, with 33 funds opening new positions, 49 increasing their positions, 48 reducing their positions, and 23 closing their positions.
43% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 23
5% more funds holding
Funds holding: 149 → 157 (+8)
2.19% more ownership
Funds ownership: 83.33% → 85.52% (+2.2%)
2% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 48
14% less capital invested
Capital invested by funds: $1.2B → $1.03B (-$173M)
31% less call options, than puts
Call options by funds: $3.07M | Put options by funds: $4.45M
50% less funds holding in top 10
Funds holding in top 10: 6 → 3 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VPC
Vestal Point Capital
New York
|
+$18.3M |
| 2 |
DM
Deerfield Management
New York
|
+$16.9M |
| 3 |
ECM
Estuary Capital Management
Wayzata,
Minnesota
|
+$15M |
| 4 |
B
Braidwell
Stamford,
Connecticut
|
+$12.6M |
| 5 |
ABG
Ally Bridge Group
New York
|
+$7.84M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$25.5M |
| 2 |
FTM
First Turn Management
Del Mar,
California
|
-$21.8M |
| 3 |
BlackRock
New York
|
-$7.29M |
| 4 |
NIP
Nicholas Investment Partners
Rancho Santa Fe,
California
|
-$5.98M |
| 5 |
SCM
Superstring Capital Management
New York
|
-$5.78M |
DAWN Hedge Fund Activity: Q2 2024 in Review
157 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in Day One Biopharmaceuticals (DAWN) for Q2 2024, worth a combined $1.03B — down 14% from $1.2B a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new DAWN positions and 23 closed out — a net gain of 10 holders — while 49 added to existing stakes and 48 trimmed.
The largest buyer was Vestal Point Capital, opening a new position worth an estimated $18.3M. The largest seller was Fidelity Investments, cutting an estimated $25.5M.
- 157 institutional investors held Day One Biopharmaceuticals (DAWN) as of Q2 2024, up from 149 in Q1 2024.
- Funds reported $1.03B of Day One Biopharmaceuticals stock for Q2 2024, down 14% quarter-over-quarter.
- 33 funds opened new Day One Biopharmaceuticals positions in Q2 2024 and 23 closed out, a net change of +10 holders.
- The largest Day One Biopharmaceuticals buyer in Q2 2024 was Vestal Point Capital, an estimated $18.3M added.
- The largest Day One Biopharmaceuticals seller in Q2 2024 was Fidelity Investments, an estimated $25.5M sold.
Based on aggregated 13F filings for Q2 2024.